Therapeutic Antibodies

Antibody-enhancing technologies

Kyowa Kirin owns proprietary antibody-enhancing technologies, POTELLIGENT® and COMPLEGENT®.


Antibody is composed of sugar chains and polypeptide chains.

We discovered that removal of a sugar residue called fucose from the sugar chains lead to enhancement of ADCC activity of the therapeutic antibody.

COMPLEGENT® technology

Using protein engineering technology, we created "isotype-chimeric" antibody with enhanced CDC activity.

AccretaMab® technology

AccretaMab® is the result of our proprietary antibody enhancing technologies, POTELLIGENT® and COMPLEGENT®.
AccretaMab® features the ultimate combination of enhanced ADCC and CDC effector function.